Filing Flows › RxSight (RXST) › Q2 2026 › vs Q2 2025
RxSight (RXST) Q2 2026 vs Q2 2025 (year over year)
RxSight's revenue rose $104K (+0.3%) from $33.6M in Q2 2025 to $33.7M in Q2 2026. The biggest changes: License and Collaboration Revenue +$6.5M (—); Product −$6.4M (-19%).
RxSight, Q2 2026: revenue $33.7M (+0.3% year over year), operating margin -40.8%, net loss $12.1M, operating cash flow −$9.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Rxlal | $24.5M | $27.0M | −$2.5M | -9% |
| Service Warranty Service Contracts and Accessories | $1.4M | $1.5M | −$94K | -6% |
| LDD | $1.3M | $5.1M | −$3.8M | -74% |
| Product | $27.2M | $33.6M | −$6.4M | -19% |
| License and Collaboration Revenue | $6.5M | $0 | $6.5M | — |
| Revenue | $33.7M | $33.6M | $104K | +0.3% |
| Other income, net | $1.8M | $2.2M | −$488K | -22% |
| Net loss | $12.1M | $11.8M | $311K | +3% |
| Costs & expenses | $47.6M | $47.7M | −$73K | -0.2% |
| Operating costs | $47.5M | $47.6M | −$129K | -0.3% |
| Income tax | $88K | $32K | $56K | +175% |
| Research & development | $9.2M | $10.2M | −$980K | -10% |
| SG&A | $30.4M | $29.0M | $1.4M | +5% |
| Operating cash sources | $18.0M | $13.7M | $4.3M | +31% |
| Depreciation & amortization | $999K | $785K | $214K | +27% |
| Share-based compensation | $7.5M | $8.5M | −$1.1M | -13% |
| Cash used in operations | $9.5M | $4.4M | $5.2M | +118% |
| Net loss absorbed | $12.1M | $11.8M | $311K | +3% |
| Working capital & other | $5.9M | $1.9M | $4.0M | +207% |
Questions
How much did RxSight's revenue grow year over year in Q2 2026?
RxSight's revenue rose $104K (+0.3%) from $33.6M in Q2 2025 to $33.7M in Q2 2026.
What drove RxSight's revenue change in Q2 2026?
License and Collaboration Revenue +$6.5M (—); Product −$6.4M (-19%).